Related Experiment Video
Updated: May 7, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma
Soham Puvvada1, Samantha Kendrick, Lisa Rimsza
1Department of Medicine, Division of Hematology-Oncology, University of Arizona, Tucson, AZ, USA.
Cancer Genetics
|October 2, 2013
Summary
New molecular techniques are revolutionizing the understanding and treatment of diffuse large B cell lymphoma (DLBCL). These advances impact classification, identify new therapeutic targets, and highlight the tumor microenvironment's role.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Diffuse large B cell lymphoma (DLBCL) is a heterogeneous hematologic malignancy.
- Traditional classification and treatment strategies are evolving with molecular insights.
Purpose of the Study:
- To review emerging molecular techniques for DLBCL research.
- To discuss the impact of molecular data on DLBCL classification and therapeutic strategies.
- To highlight the role of the tumor microenvironment in DLBCL pathogenesis.
Main Methods:
- Review of recent literature on molecular profiling in DLBCL.
- Analysis of gene expression, DNA/RNA sequencing, and epigenetic profiling data.
- Examination of studies focusing on oncogenic pathways and tumor microenvironment.
Main Results:
- Molecular techniques have refined DLBCL classification and identified new disease entities.
- Understanding altered cell survival pathways has led to novel therapeutic targets.
- The tumor microenvironment is increasingly recognized as critical in DLBCL development.
Conclusions:
- Molecular profiling is essential for advancing DLBCL diagnosis and treatment.
- Targeting specific oncogenic pathways and the tumor microenvironment offers promising therapeutic avenues.
- Continued research in molecular genetics will further personalize DLBCL management.
Keywords:
B cell receptor signalingDiffuse large B cell lymphomagene expression profilingoncogenestumor microenvironmentMore Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...